Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761(R))

Mild cognitive impairment (MCI) and dementia are clinically prevalent in the elderly. There is a high risk of cognitive decline in patients diagnosed with MCI or dementia. This review describes the effectiveness of Ginkgo biloba leaf special extract EGb 761(R) for the treatment of dementia syndromes and EGb 761(R) combination therapy with other medications for symptomatic dementia. This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia. Currently, there is little evidence to support the combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EGb 761(R) in mixed therapy.

Automated summary

Ginkgo biloba leaf special extract EGb 761(R) has demonstrated effectiveness in improving cognitive function and neuropsychiatric symptoms in patients with age-related cognitive decline, MCI, and mild to moderate dementia, reducing caregiver stress and maintaining patient autonomy. Further evidence is needed to evaluate the role of EGb 761(R) in combination therapy with anti-dementia drugs.